Second SPMS Patient Given Foralumab Continues to Improve Findings are consistent with those seen in the first non-active SPMS patient
Six months of treatment with foralumab nasal spray led to significant functional improvements in the second patient with non-active secondary progressive multiple sclerosis (SPMS) who received treatment under a single-patient expanded access program.
Findings from this patient have been generally consistent with those seen in the first non-active SPMS patient, who also experienced clinical improvement after six months of treatment.
Non-active SPMS is a secondary form of disease in which patients experience continuous disability progression in the absence of relapses. SPMS has a significant unmet need for effective treatments; mitoxantrone is the only approved disease-modifying treatment approved in the U.S. for this type of MS.
Based on data from the first two patients, the U.S. Food and Drug Administration (FDA) cleared a special access program at Harvard Medical School’s Brigham and Women’s Hospital in Massachusetts to test foralumab in up to eight more patients.
“I am truly excited and encouraged by the clinical benefits shown so far for the first two expanded access patients receiving intranasal foralumab for SPMS,” Gabriele Cerrone, executive chairman and interim CEO of Tiziana Life Sciences, said in a press release.
"This program is a top priority for us, and we expect to enroll four additional patients with SPMS at Brigham and Women’s Hospital (BWH) in [the fourth quarter of] 2022,” added Cerrone.
Tiziana‘s foralumab is designed to reduce inflammation by targeting CD3, a protein receptor found on immune T-cells. In animal models, the treatment suppressed the activity of inflammatory T-cell subsets, while enhancing the function of regulatory T-cells, which repress the inflammatory activity of other types of immune cells.
The complete exciting article can be found here: https://multiplesclerosisnewstoday.c...ven-foralumab/
Six months of treatment with foralumab nasal spray led to significant functional improvements in the second patient with non-active secondary progressive multiple sclerosis (SPMS) who received treatment under a single-patient expanded access program.
Findings from this patient have been generally consistent with those seen in the first non-active SPMS patient, who also experienced clinical improvement after six months of treatment.
Non-active SPMS is a secondary form of disease in which patients experience continuous disability progression in the absence of relapses. SPMS has a significant unmet need for effective treatments; mitoxantrone is the only approved disease-modifying treatment approved in the U.S. for this type of MS.
Based on data from the first two patients, the U.S. Food and Drug Administration (FDA) cleared a special access program at Harvard Medical School’s Brigham and Women’s Hospital in Massachusetts to test foralumab in up to eight more patients.
“I am truly excited and encouraged by the clinical benefits shown so far for the first two expanded access patients receiving intranasal foralumab for SPMS,” Gabriele Cerrone, executive chairman and interim CEO of Tiziana Life Sciences, said in a press release.
"This program is a top priority for us, and we expect to enroll four additional patients with SPMS at Brigham and Women’s Hospital (BWH) in [the fourth quarter of] 2022,” added Cerrone.
Tiziana‘s foralumab is designed to reduce inflammation by targeting CD3, a protein receptor found on immune T-cells. In animal models, the treatment suppressed the activity of inflammatory T-cell subsets, while enhancing the function of regulatory T-cells, which repress the inflammatory activity of other types of immune cells.
The complete exciting article can be found here: https://multiplesclerosisnewstoday.c...ven-foralumab/
Comment